Benjamin Hohl, CHIEF FINANCIAL OFFICER at Enliven Therapeutics, Inc. (ELVN), sold 6,500 shares at $21.59 ($140K) on 2025-01-27, disclosed to the SEC on 2025-01-29.
Scheduled sale ($140k) by CHIEF FINANCIAL OFFICER under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $21.59 | 3,250 | $70K | 50.0% |
| 2 | $21.59 | 3,250 | $70K | 50.0% |
| Total | $21.59 avg | 6,500 | $140K | 100% |
| Filing → |
| ELVN | SELL | 2026-07-21 | $317K | — | Filing → |
| ELVN | SELL | 2026-06-22 | $264K | — | Filing → |
| ELVN | SELL | 2026-03-10 | $296K | — | Filing → |